R. Abdelrahman

发表

Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs

W. Slikker, J. Fisher, J. N. van den Anker, 2020, Pharmaceutics.

Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

A. Tefferi, T. Lasho, A. Pardanani, 2013, American journal of hematology.

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

A. Tefferi, W. Hogan, M. Litzow, 2014, Leukemia.

Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib

A. Tefferi, W. Hogan, M. Litzow, 2014, Leukemia.

Momelotinib treatment‐emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis

A. Tefferi, W. Hogan, M. Litzow, 2015, British journal of haematology.

CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value

C. Brooks, A. Tefferi, A. Pardanani, 2016, Leukemia.

Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine–phenotype study

A. Tefferi, A. Pardanani, C. Hanson, 2013, Leukemia.

ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis

A. Tefferi, T. Lasho, R. Ketterling, 2015, British journal of haematology.

Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis

A. Tefferi, J. Butterfield, A. Pardanani, 2013, Leukemia.

Momelotinib treatment‐emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis

A. Tefferi, W. Hogan, M. Litzow, 2015, British Journal of Haematology.